Odronextamab bla accepted for fda review for the treatment of relapsed/refractory follicular lymphoma

Tarrytown, n.y., feb. 26, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. food and drug administration (fda) has accepted for review the resubmission of the biologics license application (bla) for odronextamab in relapsed/refractory (r/r) follicular lymphoma (fl) after two or more lines of systemic therapy.
REGN Ratings Summary
REGN Quant Ranking